B lymphocytes and B-cell activating factor promote collagen and profibrotic markers expression by dermal fibroblasts in systemic sclerosis - Wikidata - wikimedia - TriplyDB

B lymphocytes and B-cell activating factor promote collagen and profibrotic markers expression by dermal fibroblasts in systemic sclerosis

B lymphocytes and B-cell activating factor promote collagen and profibrotic markers expression by dermal fibroblasts in systemic sclerosis

http://www.wikidata.org/entity/Q37690672

about

B-cell depletion attenuates serological biomarkers of fibrosis and myofibroblast activation in IgG4-related disease Current perspectives on the immunopathogenesis of systemic sclerosis Polychromatic flow cytometry in evaluating rheumatic disease patients Rituximab in diffuse cutaneous systemic sclerosis: should we be using it today?Immunology of IgG4-related disease.Imatinib mesylate for the treatment of steroid-refractory sclerotic-type cutaneous chronic graft-versus-host disease.Distribution and significance of interstitial fibrosis and stroma-infiltrating B cells in tongue squamous cell carcinoma Safety and tolerability of an anti-CD19 monoclonal antibody, MEDI-551, in subjects with systemic sclerosis: a phase I, randomized, placebo-controlled, escalating single-dose study.B Cell Homeostasis and Functional Properties Are Altered in an Hypochlorous Acid-Induced Murine Model of Systemic Sclerosis.Potential approaches to reverse or repair renal fibrosis.Crosstalk between fibroblasts and inflammatory cells.The role of the acquired immune response in systemic sclerosis.T and NK Cell Phenotypic Abnormalities in Systemic Sclerosis: a Cohort Study and a Comprehensive Literature Review.Potential of glycosylation research in graft versus host disease after allogeneic hematopoietic stem cell transplantation.B lymphocytes in renal interstitial fibrosis.Proteoglycan expression correlates with the phenotype of malignant and non-malignant EBV-positive B-cell lines.Tailored chemokine receptor modification improves homing of adoptive therapy T cells in a spontaneous tumor model.B cells tell scleroderma fibroblasts to produce collagen.Targeting B lymphocytes in progressive fibrosing mediastinitis.B cell depletion therapy upregulates Dkk-1 skin expression in patients with systemic sclerosis: association with enhanced resolution of skin fibrosis.Niclosamide Prevents Systemic Sclerosis in a Reactive Oxygen Species-Induced Mouse Model.Two years follow-up of an open-label pilot study of treatment with rituximab in patients with early diffuse cutaneous systemic sclerosis.Belimumab for the Treatment of Early Diffuse Systemic Sclerosis: Results of a Randomized, Double-Blind, Placebo-Controlled, Pilot Trial.Breg Cells Are Numerically Decreased and Functionally Impaired in Patients With Systemic Sclerosis.Scleroderma Peripheral B Lymphocytes Secrete Interleukin-6 and Transforming Growth Factor β and Activate Fibroblasts.Use of biologics and other novel therapies for the treatment of systemic sclerosis.Properties and Immune Function of Cardiac Fibroblasts.Changes in T cell and B cell composition in discoid lupus erythematosus skin at different stages.Characterization of inflammatory cell infiltrate of scleroderma skin: B cells and skin score progression.

P2860

Q24658641-DC253F25-A2B0-4003-B1F0-7DA71EDC5D68 Q26741264-6704876A-7E36-4009-9EB3-E68003CA980B Q26827075-FB83CA8C-9CDF-4D24-9E5B-DE6383DBC26C Q27022117-63183D96-E0B0-4D09-958E-06B3DA30BF58 Q34471314-51DCB190-B6C5-463D-9CAA-7FFD24AB5E90 Q35588726-8F99A31A-DFFE-4A84-BE98-4E55028AD6AB Q36640353-A9EA4E06-B1BF-49A6-B4D2-9B814861AC64 Q36975931-573BB6EF-1F62-485A-9035-2D2EEBBFEF6B Q37627201-BAFED5CB-99FA-4975-A6D0-FA2570F4CA24 Q38186986-54358163-4016-46A5-9B7D-471883D70EB2 Q38204265-414752E8-D7F9-4D6D-AB0B-F88C6537D77A Q38543690-9B69740D-A3D2-46D2-85B5-4DA435EF049D Q38601631-94CCF8E1-9624-444A-81DC-C8DEB004B019 Q38753771-D1570DD1-F6FC-4FDC-94F8-B4952D63FAAD Q38756261-972EC39A-7367-4EF5-A47A-A1555393FB88 Q38822694-E351834D-9DF7-47EC-A3C4-8285A00B7E41 Q39985240-486D9ACB-4CA5-4FCE-B3C1-2B6BA9A5D500 Q40828244-EA897E2E-8480-4870-9008-B0D9FF5D68B1 Q42763843-9C78F076-C309-4424-84D9-DA89FF0B2222 Q42771422-3CB2170E-6663-42BD-B4A8-06F3618672BE Q46491430-8A2F2176-49A9-4928-BA24-4EF606705C39 Q47777296-F29B6281-FD01-4DFE-84B5-8AA864CFFEE7 Q48121915-288A21F1-5C6B-48BB-86E8-E46C127F4CBA Q50705723-C35F4EB8-6B25-4CF8-9376-EEA784C9A91F Q51250934-9AA98069-F4C0-4E18-BD66-598DBCC09770 Q51297193-65D4DBC8-4F0F-490E-8862-3A539D45BAE2 Q51835859-4AC384EC-0FA2-4B59-A402-D782B25B1E16 Q52943492-824AA6DB-BA8C-44E0-8630-A68CEF9D9386 Q55261205-C7664892-9C28-4BED-AA79-6BBF4A9D86DB

P2860

B lymphocytes and B-cell activating factor promote collagen and profibrotic markers expression by dermal fibroblasts in systemic sclerosis

http://www.wikidata.org/entity/Q37690672

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on 28 October 2013

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

B lymphocytes and B-cell activ ...... roblasts in systemic sclerosis

@en

B lymphocytes and B-cell activ ...... oblasts in systemic sclerosis.

@nl

type

label

B lymphocytes and B-cell activ ...... roblasts in systemic sclerosis

@en

B lymphocytes and B-cell activ ...... oblasts in systemic sclerosis.

@nl

prefLabel

B lymphocytes and B-cell activ ...... roblasts in systemic sclerosis

@en

B lymphocytes and B-cell activ ...... oblasts in systemic sclerosis.

@nl

P1433

Q37690672-31882AC3-5A61-488A-977B-6EBC4B187132

P1476

Q37690672-789E6277-65D0-424D-A90F-05F8D52AC250

P2093

Q37690672-178FC91B-3F9A-4462-AF85-795C70390270

Q37690672-28F1920E-03EA-4EBC-80DB-846B32CDF46A

Q37690672-9431D45D-4943-42D5-836C-0220C34C0AFC

Q37690672-9D26B2C9-40D6-4A64-A69F-688FADB87005

Q37690672-CFA2B7E9-833B-49EC-AB77-CA453D77680E

P2860

Q37690672-006E2C00-9C03-4E27-A0D2-D50DF649CCCF

Q37690672-0CA95F3C-2FA0-4B96-AEFE-25B614ECA295

Q37690672-114F0E6B-EBC8-4E8A-8AF7-E6C94C3DA6B8

Q37690672-15516AFD-1A57-49BE-857B-DD490028F600

Q37690672-1CDAE983-DBF0-453D-AFFC-BBB94B1F2B28

Q37690672-26AE4A0C-B911-4E0D-A154-C2DFEB488FA5

Q37690672-2A90656D-0B43-4F2F-AC77-F3FB142E5568

Q37690672-2EAB646B-AF1E-48B8-B51B-5B5190B77815

Q37690672-2F801C06-EE4E-45C1-B826-E7612DACD422

Q37690672-2FE7FC40-779F-43D8-A5F1-60311F5EF91A

P2888

Q37690672-AC3268A0-28E6-4735-BFB2-FBF393E9763E

P304

Q37690672-136ED25D-158E-4B3F-8966-B7BCEB3E4CB4

P31

Q37690672-6E37485A-925E-43AF-BD94-76199E505F28

P356

Q37690672-897AEF71-7885-44AF-BEAA-2A35C84B7E93

P433

Q37690672-09EC3407-F9BE-4488-BB84-A7790279E57F

P478

Q37690672-1F86EEC6-2875-4AF3-89D2-E272F59F6C9C

P50

Q37690672-226C2770-202A-40FE-86D6-7796B26B0214

Q37690672-DC5E0F41-115D-46A1-8BA0-238E7430931C

P577

Q37690672-14046171-6D3C-4548-8A1E-B30B0A7C81ED

P5875

Q37690672-D4F21329-402E-4559-B74C-BDCAA254D58F

P6179

Q37690672-0FFD4065-6567-4B96-8868-B74B8A1EC5AD

P698

Q37690672-D36E36A9-7403-4657-9959-55FF50633934

P921

Q37690672-66694B26-A305-4793-B3E5-BABF993C7A8D

P932

Q37690672-C6D6B2BD-DC9C-4654-9D1A-00D7026E7037

P356

P1433

Arthritis Research and Therapy

P1476

B lymphocytes and B-cell activ ...... roblasts in systemic sclerosis

@en

P2093

Antoine François

http://www.w3.org/2001/XMLSchema#string

Dominique Wachsmann

http://www.w3.org/2001/XMLSchema#string

Emmanuel Chatelus

http://www.w3.org/2001/XMLSchema#string

Jacques-Eric Gottenberg

http://www.w3.org/2001/XMLSchema#string

Jean Sibilia

http://www.w3.org/2001/XMLSchema#string

P2860

Elevated matrix metalloproteinase-9 in patients with systemic sclerosis

B cell-activating factor belonging to the TNF family (BAFF)-R is the principal BAFF receptor facilitating BAFF costimulation of circulating T and B cells

B cell depletion in diffuse progressive systemic sclerosis: safety, skin score modification and IL-6 modulation in an up to thirty-six months follow-up open-label trial.

Criteria for the classification of early systemic sclerosis.

B-lymphocyte depletion reduces skin fibrosis and autoimmunity in the tight-skin mouse model for systemic sclerosis

Serum TIMP-1, TIMP-2, and MMP-1 in patients with systemic sclerosis, primary Raynaud's phenomenon, and in normal controls.

Systemic sclerosis: a prototypic multisystem fibrotic disorder.

Regulatory mechanisms for the production of BAFF and IL-6 are impaired in monocytes of patients of primary Sjögren's syndrome

Altered B lymphocyte function induces systemic autoimmunity in systemic sclerosis.

The role of BAFF in immune function and implications for autoimmunity.

P2888

P304

R168

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1186/AR4352

http://www.w3.org/2001/XMLSchema#string

P433

5

http://www.w3.org/2001/XMLSchema#string

P478

15

http://www.w3.org/2001/XMLSchema#string

P50

P577

2013-10-28T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

259107032

http://www.w3.org/2001/XMLSchema#string

P6179

1038299312

http://www.w3.org/2001/XMLSchema#string

P698

24289101

http://www.w3.org/2001/XMLSchema#string

P921

P932

3978899

http://www.w3.org/2001/XMLSchema#string